In response to reports of some patients taking Pfizer Inc.’s COVID-19 treatment, Paxlovid (nirmatrelvir and ritonavir), experiencing a return of the disease, CEO Albert Bourla advised in a 3 May Bloomberg interview that if that happens, they can take more of the drug. But the US Food and Drug Administration spoke out against the idea.
Bourla suggested in the interview that if patients experience a return of infection after taking a full course of Paxlovid, they can go